Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
In this review, the authors discuss “actinopathies” in terms of the clinical aspects and cellular mechanisms, with a focus on the effect of these mutations on neutrophil function.…
Michael Banks, MD, announces the faculty of The Doctor’s Channel’s upcoming Cases in Thoracic Oncology series. Expert faculty Ross Camidge, MD, PhD, and Erin Schenk, MD, PhD, will…
Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, discusses promising results from current clinical trials for newly diagnosed multiple myeloma. The GRIFFIN trial…
Mark Ballow, MD, of the University of South Florida, and Jolan Walter, MD, PhD, of the University of South Florida and Johns Hopkins All Children’s Hospital, discuss COVID-19…
In an interview conducted during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute in…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Brian G. M. Durie, MD, chairman of the board of the International Myeloma Foundation, discusses whether patients with borderline high-risk smoldering myeloma should begin treatment early. Some treatments…
At the first virtual Immunotherapy Patient Summit, Leena Gandhi, MD, PhD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the latest immunotherapy options for patients with lung cancer. Immunotherapy…
In a sequencing study of 82 patients with smoldering multiple myeloma, there were fewer NRAS and FAM46C mutations and with fewer adverse translocations – del(1p), del(14q), del(16q), and…
